Plasma autoantibody biomarkers for basal like breast cancer

Patent metadata

Field	Value
Publication number	US-11525831-B2
Application number	US-202016743906-A
Country	US
Kind code	B2
Filing date	Jan 15, 2020
Priority date	Dec 9, 2014
Publication date	Dec 13, 2022
Grant date	Dec 13, 2022

Abstract

Cancer patients make antibodies to tumor-derived proteins that are potential biomarkers for early detection. Twenty-eight antigens have been identified as potential biomarkers for the early detection of basal-like breast cancer (Tables 1, 2). Also, a 13-AAb classifier has been developed that differentiate patients with BLBC from healthy controls with 33% sensitivity at 98% specificity (Table 3).

First claim

The invention claimed is:

1. A method comprising:
contacting a serum or plasma sample obtained from a human subject to a panel of tumor antigens, wherein said human subject is a female patient less than 50 years old; and
detecting binding of at least four tumor antigens with antibodies in the serum or plasma sample, wherein the at least four tumor antigens are detectably labeled and comprises: P53 (TP53), NYESO1 (CTAG1B), NY ESO2 (CTAG2), and PPHLN1.

2. The method of claim 1 , wherein said detecting comprises utilizing an enzyme-linked immunosorbant assay (ELISA).

3. The method of claim 1 , wherein said at least four tumor antigens comprise PPHLN1, RNF216, P53 (TP53), NYESO1 (CTAG1B) and NY ESO2 (CTAG2).

4. The method of claim 1 , wherein said detecting occurs at a specificity of at least 97.9%.

5. The method of claim 1 , wherein the detectable label is a labeled secondary antibody.

6. A method comprising:
(i) obtaining a serum or plasma sample from a human;
(ii) contacting the serum or plasma sample to a panel of detectably labeled tumor antigens comprising P53 (TP53), NY-ESO1 (CTAG1B), NY-ESO2 (CTAG2), and PPHLN1; and
(iii) analyzing proteins in the contacted sample for the presence of autoantibodies specific for at least 3 tumor antigens of the panel, wherein analyzing comprises an enzyme-linked immunosorbent assay (ELISA).

7. The method of claim 6 , wherein the panel further comprises one or more detectably labeled tumor antigens selected from RNF216, PIP4K2C, ZBTB16, TAS2R8, WBP2NL, DOK2, PSRC1, MN1, TRIM21, POU4F1, SSMEM1, LMO4, BCL2, KRT8, TSGA13, PVRL4, SNRK, DYRK3, RNF32, JUNB, KCNIP3, CCDC68, CSN3, and TRAIP.

8. The method of claim 6 , wherein the detectable label is a labeled secondary antibody.

Assignees

• Univ Arizona State
• Us Health

Inventors

• Labaer Joshua
• Wang Jie
• Qui Ji
• Wallstrom Garrick
• Anderson Karen
• Park Jin
• Figueroa Jonine

Classifications

• G01N33/57515 Primary

  of the breast · CPC title

• C12Q1/6886

  for cancer (immunoassay for cancer G01N33/575) · CPC title

• C12Q2600/158

  Expression markers · CPC title

• C07K16/3015

  Breast · CPC title

• C12Q2600/118

  Prognosis of disease development · CPC title